Response of Anaplastic Thyroid Tumors to VEGF-Trap, an Anti-Angiogenic Agent

Isabella Rossi  
*Illinois Wesleyan University*

Fiemu Nwariaku, Faculty Advisor  
*University of Texas-Southwestern Medical Center*

Follow this and additional works at: https://digitalcommons.iwu.edu/jwprc

Rossi, Isabella and Nwariaku, Faculty Advisor, Fiemu, "Response of Anaplastic Thyroid Tumors to VEGF-Trap, an Anti-Angiogenic Agent" (2009). *John Wesley Powell Student Research Conference*. 23.  
https://digitalcommons.iwu.edu/jwprc/2009/posters/23

This is protected by copyright and/or related rights. It has been brought to you by Digital Commons @ IWU with permission from the rights-holder(s). You are free to use this material in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/or on the work itself. This material has been accepted for inclusion by faculty at Illinois Wesleyan University. For more information, please contact digitalcommons@iwu.edu.  
©Copyright is owned by the author of this document.
RESPONSE OF ANAPLASTIC THYROID TUMORS TO VEGF-TRAP, 
AN ANTI-ANGIOGENIC AGENT

Isabella Rossi and Fiemu Nwariaku*
Biology Department, Illinois Wesleyan University and 
University of Texas Southwestern Medical Center

Vascular Endothelial Growth Factor (VEGF) is the major proangiogenic factor secreted by tumor cells. VEGF causes endothelial cell proliferation, migration, and survival, leading to the formation of new blood vessels that are essential for tumor growth and metastases. Anti-VEGF therapy involving an anti-VEGF monoclonal antibody has been successfully used to treat a variety of cancers. However, this approach has met with mixed results. A recently developed antibody, VEGF-Trap, was developed to improve the efficacy of anti-VEGF strategies. VEGF-Trap is a synthetic protein composed of the VEGF-binding domains VEGF Receptor 1 (VEGFR1) and VEGFR2, resulting in a higher binding affinity for VEGF than the monoclonal antibody. This study determined the effect of VEGF-Trap in anaplastic thyroid carcinoma, an aggressive form of cancer with high mortality and metastases rates. Mice bearing anaplastic tumors showed improved survival when treated with VEGF-Trap. The size of the tumors, in addition to the microvessel density, significantly decreased. Additionally, the results indicated compensatory VEGF production as well as an increase in macrophage density. Overall, the study showed anaplastic thyroid cancer to be susceptible to treatment with VEGF-Trap. Potential resistance of tumor blood vessels to anti-VEGF therapy is hypothesized to be conferred by pericytes, which provide survival signals for blood vessels. Therefore, a dual targeting of both endothelial cells and pericytes by combining VEGF-trap with an anti-PDGF therapy may prove to be a more efficient anti-angiogenic therapy for anaplastic thyroid cancer.